Recombinant protein polymer-antibody conjugates for applications in nanotechnology and biomedicine

Goncalves, Antonio G.; Hartzell, Emily J; Sullivan, Millicent O.; Chen, Wilfred

doi:10.1016/j.addr.2022.114570

Cited by 6 publications

(4 citation statements)

References 213 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, they are ideal in biomedical engineering [ 47 ]. Diverse efforts have been invested into designing suitable ABC anticancer strategies [ 51 ] and several ABCs have been developed in several clinical trials. Nanotechnology is a powerful approach in terms of ABC-based diagnosis and therapy of cancers due to its ease in synthesis, tuneability, and bio-functionalization [ 46 , 48 ].…”

Section: Discussionmentioning

confidence: 99%

Antibody–Biopolymer Conjugates in Oncology: A Review

et al. 2023

View full text Add to dashboard Cite

Cancer is one of the most prevalent diseases and affects a large proportion of the population worldwide. Conventional treatments in the management include chemotherapy, radiotherapy, and surgery. Although being well-accepted, they have many lacunas in the form of severe side effect resulting from lack of targeted delivery. Antibody biopolymer conjugates are a novel method which is an add-on to older methods of immunization. It is used in various diseases and disorders. It ensures the targeted delivery of molecules to increase its efficacy and reduce unwanted effects of the molecule/drug to normal cells. It shows miraculous results in the treatment and management of several cancers even in advanced stages. Herein, we present the chemistry between biopolymer and antibody, their effects on cancer as well as the basic differences between antibody–drug conjugates and antibody–biopolymer conjugates.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibody–Biopolymer Conjugates in Oncology: A Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[189,190] If the hydrophobicity of the globular protein block and the IDP differs, the fusion of the globular protein with the IDP assembles in a manner similar to the assembly of amphiphilic molecules. [191,192] For example, Li et al fused a hydrophilic fluorescent globular protein, mCherry, to a hydrophobic ELP sequence containing para azido-phenylalanine (pAzF) via leucine zippers. [193] Due to the differences in hydrophobicity of mCherry and ELP domains, above the transition temperature of ELPs, the mCherryÀ ELP fusions assembled into nanovesicles with mCherry at the surface.…”

Section: Other Ordered Proteinà Idp Constructsmentioning

confidence: 99%

“…Compared to sequences with specific secondary structures, ordered globular protein domains typically contain multiple secondary structures [189,190] . If the hydrophobicity of the globular protein block and the IDP differs, the fusion of the globular protein with the IDP assembles in a manner similar to the assembly of amphiphilic molecules [191,192] . For example, Li et al.…”

Section: Other Ordered Protein−idp Constructsmentioning

confidence: 99%

Genetically Fusing Order‐Promoting and Thermoresponsive Building Blocks to Design Hybrid Biomaterials

Patkar,

Wang,

Mosquera

et al. 2024

Chemistry A European J

View full text Add to dashboard Cite

The unique biophysical and biochemical properties of intrinsically disordered proteins (IDPs) and their recombinant derivatives, intrinsically disordered protein polymers (IDPPs) offer opportunities for producing multistimuli‐responsive materials; their sequence‐encoded disorder and tendency for phase separation facilitate the development of multifunctional materials. This review highlights the strategies for enhancing the structural diversity of elastin‐like polypeptides (ELPs) and resilin‐like polypeptides (RLPs), and their self‐assembled structures via genetic fusion to ordered motifs such as helical or beta sheet domains. In particular, this review describes approaches that harness the synergistic interplay between order‐promoting and thermoresponsive building blocks to design hybrid biomaterials, resulting in well‐structured, stimuli‐responsive supramolecular materials ordered on the nanoscale.

show abstract

“…In addition to polymeric carriers, other encapsulation techniques such as coacervation, microencapsulation, or spray drying can also be employed for nanobody formulations. Coacervation involves the phase separation of a polymer solution to form droplets that encapsulate the nanobodies [63]. Microencapsulation utilizes techniques like emulsion or solvent evaporation to form small capsules containing the nanobodies [64].…”

Section: Encapsulation Techniquementioning

confidence: 99%

Nanobodies as Spray and Aerosol Particles: A Breakthrough in Treating Respiratory Viral Infections

Mustafa,

Mohammed

2023

Preprint

View full text Add to dashboard Cite

Respiratory viral infections, including influenza, respiratory syncytial virus (RSV), and, more recently, the coronavirus disease 2019 (COVID-19) pandemic, continue to pose significant global health threats. Conventional treatments for these infections often face challenges such as limited efficacy, the emergence of drug-resistant strains, and the requirement for frequent administration. In recent years, nanobodies have emerged as a promising class of therapeutic agents due to their unique properties, including small size, high stability, and specific binding capabilities. This mini-review article focuses on the application of nanobodies as spray and aerosol particles for the treatment of respiratory viral infections. Furthermore, we highlight the remarkable efficacy of nanobodies in preclinical and clinical studies against respiratory viruses, including their ability to neutralize viral particles, inhibit viral replication, and modulate the host immune response. We discuss the potential advantages of using nanobodies as inhalable formulations, including their improved delivery to the respiratory tract, enhanced stability in aerosol form, and reduced systemic side effects. Additionally, we explore the various strategies employed to engineer nanobodies for optimal aerosol delivery, such as conjugation to carrier particles or formulation as dry powders. We also examine the potential challenges and limitations associated with the development of nanobody-based aerosol therapies, including production scalability, cost-effectiveness, and regulatory considerations.

show abstract

Recombinant protein polymer-antibody conjugates for applications in nanotechnology and biomedicine

Cited by 6 publications

References 213 publications

Antibody–Biopolymer Conjugates in Oncology: A Review

Antibody–Biopolymer Conjugates in Oncology: A Review

Genetically Fusing Order‐Promoting and Thermoresponsive Building Blocks to Design Hybrid Biomaterials

Nanobodies as Spray and Aerosol Particles: A Breakthrough in Treating Respiratory Viral Infections

Contact Info

Product

Resources

About